What is HC Wainwright's Estimate for MDGL Q1 Earnings?

Key Points

• HC Wainwright estimates a Q1 2027 loss of $0.29 per share for Madrigal Pharmaceuticals and maintains a Strong Buy rating. It forecasts EPS of $1.60, $3.13 and $4.16 for Q2, Q3 and Q4 2027, respectively.
• Madrigal’s latest reported quarter significantly beat estimates, with EPS of $1.83 versus a projected $1.09 loss and revenue of $431.3 million versus $404.2 million expected.
• Analyst sentiment is broadly positive: MarketBeat reports a Moderate Buy consensus and an average price target of $706.87, while legal investigations and questions about sustaining profitability remain risks.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - Analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for Madrigal Pharmaceuticals in a research note issued on Wednesday, November 4th. HC Wainwright analyst A. Ghosh expects that the biopharmaceutical company will post earnings per share of ($0.29) for the quarter. HC Wainwright has a "Strong-Buy" rating on the stock. The consensus estimate for Madrigal Pharmaceuticals' current full-year earnings is ($7.03) per share. HC Wainwright also issued estimates for Madrigal Pharmaceuticals' Q2 2027 earnings at $1.60 EPS, Q3 2027 earnings at $3.13 EPS and Q4 2027 earnings at $4.16 EPS.

Other analysts also recently issued reports about the stock. The Goldman Sachs Group assumed coverage on shares of Madrigal Pharmaceuticals in a research report on Thursday, September 24th. They issued a "buy" rating and a $704.00 target price for the company. Truist Financial restated a "buy" rating and set a $743.00 price target (up from $709.00) on shares of Madrigal Pharmaceuticals in a report on Wednesday. Canaccord Genuity Group lifted their price objective on shares of Madrigal Pharmaceuticals from $612.00 to $633.00 and gave the company a "buy" rating in a research note on Wednesday. Barclays decreased their price objective on shares of Madrigal Pharmaceuticals from $964.00 to $962.00 and set an "overweight" rating for the company in a report on Monday, August 3rd. Finally, Citigroup increased their target price on shares of Madrigal Pharmaceuticals from $725.00 to $760.00 and gave the stock a "buy" rating in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $706.87.

Madrigal Pharmaceuticals Price Performance

Shares of MDGL opened at $400.43 on Thursday. The firm has a market cap of $9.25 billion, a PE ratio of -66.96 and a beta of -0.98. The firm's 50 day moving average price is $492.40 and its 200 day moving average price is $498.45. The company has a debt-to-equity ratio of 0.65, a quick ratio of 2.94 and a current ratio of 3.20. Madrigal Pharmaceuticals has a twelve month low of $353.54 and a twelve month high of $615.00.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last announced its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.09) by $2.92. Madrigal Pharmaceuticals had a negative return on equity of 27.93% and a negative net margin of 10.89%. The business had revenue of $431.27 million during the quarter, compared to analyst estimates of $404.17 million. During the same period in the previous year, the company earned ($5.08) EPS.

Insider Activity at Madrigal Pharmaceuticals

In other Madrigal Pharmaceuticals news, General Counsel Shannon T. Kelley sold 664 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $514.97, for a total transaction of $341,940.08. Following the transaction, the general counsel owned 11,474 shares in the company, valued at $5,908,765.78. This trade represents a 5.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO William Sibold sold 5,221 shares of Madrigal Pharmaceuticals stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $542.39, for a total transaction of $2,831,818.19. Following the completion of the transaction, the chief executive officer directly owned 197,746 shares in the company, valued at approximately $107,255,452.94. This represents a 2.57% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 12,247 shares of company stock valued at $6,581,182. Corporate insiders own 17.60% of the company's stock.

Institutional Trading of Madrigal Pharmaceuticals

Several large investors have recently modified their holdings of MDGL. Lido Advisors LLC acquired a new position in Madrigal Pharmaceuticals in the 3rd quarter valued at $321,000. New York Life Investment Management LLC lifted its position in Madrigal Pharmaceuticals by 18.8% during the 3rd quarter. New York Life Investment Management LLC now owns 2,412 shares of the biopharmaceutical company's stock worth $1,216,000 after acquiring an additional 382 shares during the last quarter. AlphaCore Capital LLC acquired a new position in Madrigal Pharmaceuticals during the 3rd quarter worth $466,000. Brighton Jones LLC bought a new stake in Madrigal Pharmaceuticals during the third quarter valued at about $988,000. Finally, Ethic Inc. boosted its holdings in Madrigal Pharmaceuticals by 20.6% during the third quarter. Ethic Inc. now owns 598 shares of the biopharmaceutical company's stock valued at $301,000 after acquiring an additional 102 shares during the period. 98.50% of the stock is owned by institutional investors.

More Madrigal Pharmaceuticals News

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Q3 results substantially beat expectations. Madrigal reported earnings of $1.83 per share, versus the consensus estimate of a $1.09 loss, and revenue of $431.3 million, ahead of the $404.2 million estimate. Rezdiffra sales growth helped drive the results, with coverage reporting sales surpassed $1 billion. Madrigal Q3 results
• Positive Sentiment: Analysts raised price targets and maintained Buy ratings. Canaccord lifted its target to $633 from $612, Truist to $743 from $709, and Citi to $760 from $725. The upgrades reflect substantial potential upside, though targets are analysts’ estimates, not guarantees. Canaccord rating Truist rating Citi rating
• Neutral Sentiment: Clinical development continues, but key data are not imminent. Madrigal expects the MAESTRO-NASH OUTCOMES readout in late 2027 and is planning a 2,000-plus-patient MAESTRO-CSPH study. These programs offer longer-term potential, but their timelines mean they are less likely to provide a near-term catalyst. Madrigal clinical plans
• Negative Sentiment: Legal investigations and profit-sustainability questions remain risks. Two law firms announced investigations into potential securities-law violations; these are allegations under investigation, not findings of wrongdoing. Separate coverage cited investor concerns about near-term profitability, which could temper the reaction to the strong quarterly beat. Kirby McInerney investigation notice Kaplan Fox investigation notice

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for nonalcoholic steatohepatitis, now known as metabolic dysfunction-associated steatohepatitis (MASH), and other chronic liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal's lead product is Rezdiffra (resmetirom), an orally administered thyroid hormone receptor beta agonist designed to target key drivers of liver disease, including hepatic fat accumulation and fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.